Published in Oncology Business Week, November 14th, 2004
"I am extremely encouraged that we have been able to integrate ArQule's proprietary chemistry with the growing strength and stature of the ArQule Biomedical Institute," said Stephen A. Hill, president and CEO of ArQule.
"It is exciting to see the early impact of our newly appointed research leaders - Dennis France and Shi-Chung Ng, on our growing oncology portfolio," Hill said.
This newly announced program comprises a series of compounds...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week